KRAS and neoplasm: To explore whether enhancing CD8+ T cell responses to mutant KRAS inhibits tumor growth, we used an inducible lung adenocarcinoma model in which expression of oncogenic KRAS-G12D is induced after intra-tracheal delivery of Cre expressing adenovirus, Adeno-Cre19.